Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination refers to the co-administration of three distinct agents: propranolol, norfloxacin, and VSL#3. Propranolol is a non-selective beta-adrenergic receptor blocker, a small molecule pharmaceutical drug used to treat various cardiovascular conditions like hypertension, angina pectoris, and irregular heart rates, as well as non-cardiac indications such as migraine prevention, essential tremors, and anxiety. Norfloxacin is a small molecule fluoroquinolone antibiotic, effective against a broad spectrum of bacterial infections, particularly those affecting the urinary tract, prostate, gastrointestinal system, and eyes. VSL#3 is a high-potency probiotic medical food comprising eight live bacterial strains, including various Lactobacillus, Bifidobacterium, and Streptococcus species. It is used for the dietary management of conditions like irritable bowel syndrome (IBS), ulcerative colitis (UC), and pouchitis, by modulating the gut microbiota and immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propranolol + norfloxacin + VSL#3.